• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nightingale Health

0.85 EUR-0.23 %9/7 17:29
4,745 following

HEALTH

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Investor consensus
Compare
-0.23 %
-2.75 %
-37.04 %
-57.50 %
-58.54 %
-68.69 %
+1.19 %
-85.17 %
-83.50 %

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more
Market cap
51.8M EUR
Turnover
40.05K EUR
P/E (adj.) (26e)
-2.96
EV/EBIT (adj.) (26e)
-0.66
P/B (26e)
1
EV/S (26e)
2
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
1.40 EUR
Updated
2026-06-11
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 2026-06-12

Latest extensive report

Released: 2025-06-13

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Those targets are indeed quite far off, and more were just recently distributed under those same terms, so the board probably thinks the conditions are still functional. The subscription price was adjusted downward back then, but the market cap levels that trigger those options were...
7/7/2026, 6:05 AM
by Puutaheinää
3
Does anyone else find it strange that the option deal for employees is this bad? I mean, you only get to benefit when the share price is 10x current levels, and even then, the purchase price is over 2.5x higher than it is now? These kinds of moonshots are perhaps common for management...
7/6/2026, 7:32 PM
by KuinVain
3
In principle, it is possible, and in those scenarios, value is measured in a completely different way than through business metrics.
15 hours ago
by Puutaheinää
1
I would think that metabolomics data helps with development at any time. In this recent post, there is one example of how NH’s data can help in drug development:
15 hours ago
by The Ugly Buckling
1
AI giant Anthropic is starting to develop drugs (Claude Science). Does NH and its data have any chance of becoming a partner or similar in this development?
17 hours ago
by eizbee
1
I disagree. The company is trying to build strong growth on three continents simultaneously, and the adequacy of funding is a key factor over the next couple of years. It’s an absolutely essential role in the company.
20 hours ago
by Puutaheinää
1
He did, however, manage to buy €30,000 worth of Bioretec shares, so he must have had confidence in the company himself. I’m mentioning this here because I’ve been wondering what the reason could have been for resigning from both companies, Nightingale Health and Bioretec.
yesterday
by Pertti
1
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
16/9
2026

Annual report '26

5/11
2026

General meeting '26

9/3
2027

Interim report Q2'27

Press release2026-07-01 15:00

Nightingale Health and Archipelago Health partner to bring preventive screening to small-island health systems in the Crown Dependencies, Bermuda and the Caribbean

Nightingale Health
Regulatory press release2026-06-29 17:15

Nightingale Health’s Board of Directors resolved on new stock option program

Nightingale Health
Nightingale: We factored the project delay into our estimates
Research2026-06-12 09:20 by
Antti Siltanen, Antti Luiro

Nightingale: We factored the project delay into our estimates

The revenue outlook for the next fiscal year exceeds 10 MEUR.

Nightingale Health

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Nightingale's profit warning: Project delay shifts revenue to next year
Analyst Comment2026-06-09 08:40 by
Antti Siltanen

Nightingale's profit warning: Project delay shifts revenue to next year

The company's business appears to be progressing in line with our estimates.

Nightingale Health
Regulatory press release2026-06-08 18:25

Inside information, profit warning: Nightingale Health continues to grow but will not reach its 50% growth target this financial year as about EUR 2 million of revenue shifts to next financial year

Nightingale Health
Nightingale: Nightingale sings to a deaf market
Research2026-06-04 08:36 by
Antti Siltanen

Nightingale: Nightingale sings to a deaf market

The low valuation compensates for the very high level of risk.

Nightingale Health
Nightingale joins wellbeing services county research project
Analyst Comment2026-05-29 08:46 by
Antti Siltanen

Nightingale joins wellbeing services county research project

Nightingale's risk screening selects participants for lifestyle coaching.

Nightingale Health
Press release2026-05-28 10:00

Nightingale Health joins South Savo Wellbeing Services County's preventive healthcare research project in Finland

Nightingale Health
Regulatory press release2026-05-27 15:45

Nightingale Health Plc’s financial reporting and Annual General Meeting in financial year 2026–2027

Nightingale Health
New partnership for Nightingale
Analyst Comment2026-05-25 08:11 by
Antti Siltanen

New partnership for Nightingale

The new memorandum of understanding will expand blood analysis to the longevity programs in Switzerland and South Africa as early as this summer.

Nightingale Health
Press release2026-05-22 08:30

Nightingale Health and Formula 100 Health partner in preventive health: Embedding multi-disease risk detection across longevity programmes in Switzerland and South Africa

Nightingale Health
Regulatory press release2026-05-21 16:25

Nightingale Health Plc – Managers’ Transactions – Olli Karhi

Nightingale Health
Regulatory press release2026-05-18 12:02

Nightingale Health Plc: Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act (Cor Group Oy)

Nightingale Health
US market roadmap for medical devices – a European perspective
Analyst Comment2026-03-27 11:45 by
Antti Siltanen

US market roadmap for medical devices – a European perspective

Success in the US requires success in several sub-areas.

BioretecAiforia TechnologiesNightingale HealthNexstimOptomedRevenio GroupModulightBiohit
Nightingale H1'26: Research projects accelerate H2
Research2026-03-06 10:44 by
Antti Siltanen

Nightingale H1'26: Research projects accelerate H2

Nightingale's major research projects will generate revenue in H2.

Nightingale Health
Nightingale, Webcast, Half-year financial report 1 July–31 December 2025
Webcast2026-03-05 13:00

Nightingale, Webcast, Half-year financial report 1 July–31 December 2025

Nightingale Health
Regulatory press release2026-03-05 08:00

Nightingale Health's half-year report: Delivering clinical value for healthcare and moving toward 50% revenue growth, supported by a strong sales pipeline

Nightingale Health
Nightingale H1'26 preview: Revenue still relies on research projects
Analyst Comment2026-03-03 08:11 by
Antti Siltanen

Nightingale H1'26 preview: Revenue still relies on research projects

We expect revenue to grow, driven by research projects and the Terveystalo collaboration.

Nightingale Health
A step forward for Nightingale in New York
Analyst Comment2026-02-10 07:50 by
Antti Siltanen

A step forward for Nightingale in New York

The New York laboratory permit allows tests to be offered to healthcare providers without separate FDA approval.

Nightingale Health
Regulatory press release2026-02-09 20:30

Inside information: Nightingale Health achieves major milestone in the United States: New York laboratory now holds a clinical laboratory permit from New York State

Nightingale Health